title: Attenuation of post-ischemia reperfusion injury by thaliporphine and morphine in rat hearts.
abstract: Pretreatment with thaliporphine before ischemia affords cardioprotective effects against reperfusion injury via antioxidant activity. This study evaluated whether thaliporphine administered at a certain period after myocardial ischemia conferred the same cardioprotection and assessed its possible new mechanism. The left main coronary artery of anaesthetized rats was occluded for 1 h and then reperfused for 2 h. Thaliporphine was administered at 10 min before reperfusion. Controls received saline only. Morphine, a nonselective opioid receptor agonist, was used as reference compound at 0.3 mg/kg. Thaliporphine at 0.05 and 0.5 mg/kg were found to reduce the infarct size. Recovery of cardiac function was higher in thaliporphine (0.5 mg/kg) group, as assessed by a significant improvement in the rates of pressure development (+dp/dt (max)). This compound also reduced plasma creatine kinase and cardiac MPO activity. These protective effects afforded by thaliporphine were diminished by the opioid receptor antagonists (naloxone or naltrexone) and by the mitochondrial K(ATP) blocker 5HD. In comparison, morphine reduced infarct size and MPO activity in the myocardium but produced slightly improvement in cardiac function after ischemia-reperfusion. These results demonstrate that reperfusion therapy with thaliporphine protect cardiac injury through further mechanism via activation of opioid receptor and opening of mitochondrial K(ATP) channels as morphine but with stronger activity.
authors.affiliation: Institute of Pharmacology, College of Medicine, National Taiwan University, No. 1, Sec. 1, Jen-Ai Rd, Taipei, Taiwan.
authors.forename: Wei-Luen
authors.initials: WL
authors.lastname: Chang
authors.forename: Shoei-Sheng
authors.initials: SS
authors.lastname: Lee
authors.forename: Ming-Jai
authors.initials: MJ
authors.lastname: Su
mesh_terms: D000255:Adenosine Triphosphate / Q000737:chemistry; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000737:chemistry / Q000494:pharmacology; D001060:Aporphines / Q000494:pharmacology*; D003402:Creatine Kinase / Q000097:blood; D004305:Dose-Response Relationship, Drug; D006321:Heart / Q000033:anatomy & histology; D008297:Male; D008928:Mitochondria / Q000378:metabolism; D009020:Morphine / Q000494:pharmacology*; D017202:Myocardial Ischemia / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009195:Peroxidase / Q000378:metabolism; D010936:Plant Extracts; D011188:Potassium / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury; D012306:Risk; D013997:Time Factors
chemical_list: D000701:Analgesics, Opioid; D000975:Antioxidants; D001060:Aporphines; D009292:Narcotic Antagonists; D010936:Plant Extracts; D009270:Naloxone; C080702:thaliporphine; D009271:Naltrexone; D009020:Morphine; D000255:Adenosine Triphosphate; D009195:Peroxidase; D003402:Creatine Kinase; D011188:Potassium